Sarepta (SRPT) sinks 40% on Elevidys safety halt, while Sage Therapeutics (SAGE) soars on $12 cash-plus-CVR buyout by Supernus (SUPN).


Jun 16, 2025
This content is for Street Sheet Research subscribers. Click the button below to join. You'll receive our weekly research report, monthly deep-dives, and instant access to The Street Feed.
JOIN STREET SHEET RESEARCH FOR JUST $99